Identification | Back Directory | [Name]
Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- | [CAS]
1883545-42-3 | [Synonyms]
Methanesulfonamide, N-[6-[(6aR,10aR)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-3-yl]-4-hexyn-1-yl]- | [Molecular Formula]
C23H31NO4S | [MDL Number]
MFCD06411589 | [MOL File]
1883545-42-3.mol | [Molecular Weight]
417.56 |
Chemical Properties | Back Directory | [Boiling point ]
538.2±60.0 °C(Predicted) | [density ]
1.173±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -80°C | [solubility ]
<41.76mg/ml in ethanol; <41.76mg/ml in DMSO | [pka]
9.45±0.60(Predicted) |
Hazard Information | Back Directory | [Uses]
O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice[1]. | [Definition]
ChEBI: N-[6-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c][1]benzopyran-3-yl]hex-4-ynyl]methanesulfonamide is a 1-benzopyran. | [in vivo]
O-2050 (1, 3, 10, 30 mg/kg; ip; pretreatment 30 mins) produces significant and dose-dependent decreases in food intake in mice. O-2050 (10, 30 mg/kg) significantly causes locomotor stimulation[1]. | [IC 50]
CB1: 2.5 nM (Ki); CB2: 0.2 nM (Ki) | [References]
[1] Jenny L Wiley, et al. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol. 2011 Jan 25;651(1-3):96-105. DOI:10.1016/j.ejphar.2010.10.085 |
|
Company Name: |
MedChemExpress
|
Tel: |
021-58955995 |
Website: |
www.medchemexpress.com |
|